Drug Price Transparency
Stakeholder Zoom Meeting for Carriers

Annette Schuffenhauer
Chief Legal Officer
July 6, 2021
Welcome & Logistics

- Welcome & Introductions
  - Team introductions

- Logistics
  - Zoom Instructions
  - This Zoom meeting is VIDEO RECORDED

- Agenda Review
Agenda

- Drug Price Transparency Program Overview
- Reports Outstanding
- Number of Registrants
- Status of Accomplishment
- Up Next in Journey
- Listening Session – We want to hear from you!
- Contact Information – Update Information!
Drug Price Transparency Program Overview

Chapter 43.71C RCW directs the Health Care Authority to implement a drug cost transparency program through reporting from health carriers, pharmacy benefit managers, drug manufacturers and pharmacy service administrative organizations.
“Health carrier” or “carrier” means a disability insurer regulated under chapter 48.20 or 48.21 RCW, a health care service contractor as defined in RCW 48.44.010, or a health maintenance organization as defined in RCW 48.46.020, and includes “issuers” as that term is used in the patient protection and affordable care act.
HCA Reporting Requirements

- Must compile & analyze data.
- Prepare annual report for the public and the legislature synthesizing the data to demonstrate the overall impact that drug costs rebates, and other discounts have on health care premiums.
- Make a recommendation on how to provide advance notice of price increases to purchasers in WA.
Status of Accomplishments

- Posted Progress Report January 2021
- Automated the Extension request form
- Established a SFT site to submit reports
- Created a process to register and update contact information
- Solicited feedback and updated submission guide
- Provided a Tech Support inbox HCADPTTechSupport@hca.wa.gov
- Finalized Chapter 182.51 WAC
Up Next in Journey

- Update Submission Guides for October 2021 reporting
- Update registration information
- Finalize the data analytics
- Publish report for January 2022
Listening Session Prompt Questions:

- Tell us about your experience submitting reports to HCA
- What areas of the data submission process did we do well and what areas can we improve on?
- What areas of communication did we do well and what areas can we improve on?
- When should we update the data submission guide and share the new version with you so that you have enough time to review, provide comments and report your data by October 1?
- What data fields in the data submission guide did you have a difficult time understanding or interpreting?
- How can we improve our descriptions in the data submission guide, so it is clear what we are expecting?
Listening Session Prompt Questions:

- Were there any fields that you think should be nullable? If yes, why?
- Were there any fields that should allow for negative values? If yes, why?
- What sections of the data submission guide did you find confusing?
- Did you find the error log helpful? If no, how can we improve it, so it is more useful when correcting errors?
For More Information

Visit: https://www.hca.wa.gov/billers-providers-partners/prescription-drug-cost-transparency-update

Email us: drugtransparency@hca.wa.gov

Tech Support inbox HCADPTTechSupport@hca.wa.gov